TIM3+CD8+ T Cell Expression and Clinical Significance in the Central and Non-central Tumor Microenvironment of Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2024.102.46
- Author:
Jiajuan WU
1
;
Shiying GUO
2
;
Leilei LV
2
;
Jiawei ZHAI
2
;
Yu SHEN
1
;
Cheng CHEN
2
;
Qiuxia QU
1
Author Information
1. Jiangsu Institute of Clinical Immunology,
the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
2. Department of Respiratory and Critical Medicine,
the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
- Publication Type:Journal Article
- Keywords:
CD8+ T cells;
Immunotherapy;
Lung neoplasms;
PD-1;
TIM3;
Tumor microenvironment
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/metabolism*;
Lung Neoplasms/metabolism*;
Hepatitis A Virus Cellular Receptor 2/immunology*;
Tumor Microenvironment/immunology*;
CD8-Positive T-Lymphocytes/metabolism*;
Male;
Female;
Middle Aged;
Aged;
Adult;
Programmed Cell Death 1 Receptor/metabolism*;
Immunotherapy;
Clinical Relevance
- From:
Chinese Journal of Lung Cancer
2024;27(12):903-910
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:One of the most important treatment modalities for non-small cell lung cancer (NSCLC) is immune checkpoint inhibitor. Nevertheless, a small percentage of patients do not respond well to these therapies, highlighting the significance of identifying important CD8+ T cell subsets for immunotherapy and creating trustworthy biomarkers. The purpose of this study is to assess the potential utility of TIM3+CD8+ T cells as new biomarkers by examining their expressions in various areas of the NSCLC tumor microenvironment.
METHODS:Based on biopsy techniques, tumor tissue samples were obtained from patients with NSCLC and categorized into tumor central and non-central regions. Using flow cytometry, the infiltration of TIM3+CD8+ T cells and the surface expression of programmed cell death 1 (PD-1) on these cells were examined, and their correlations with the effectiveness of immunotherapy were assessed.
RESULTS:The non-central region of tumor tissues had considerably larger infiltration of TIM3+CD8+ T lymphocytes compared to the non-central region (P<0.0001). This pattern was found in both subgroups with tumor diameters ≥3 cm or <3 cm (P<0.01). In comparison to TIM3-CD8+ T cells, TIM3+CD8+ T cells showed higher levels of PD-1 (P<0.001), with more PD-1+TIM3+CD8+ T cells invading the non-central region (P<0.01). Clinical responders to immunotherapy had considerably lower infiltration levels of TIM3+CD8+ T cells in the tumor non-central region compared to non-responders, with lower levels correlated with better clinical outcomes (P<0.01), while no correlation was identified in the tumor central region (P>0.05). According to reciever operating characteristic (ROC) curve analysis, TIM3+CD8+ T cells in the tumor non-central region had an area under the curve (AUC) of 0.9375 for predicting the effectiveness of immunotherapy, which was considerably higher than that of TIM3+CD8+ T cells in the tumor central region and programmed cell death ligand 1 (PD-L1) [tumor proportion score (TPS)].
CONCLUSIONS:In the tumor microenvironment of NSCLC, TIM3+CD8+ T cells show regional distribution patterns. The expression of this cell population in the non-central region of the tumor microenvironment may be a biomarker for predicting the effectiveness of immunotherapy.
